Fluorodeoxyglucose positron emission tomography: Emerging roles in the evaluation of putative Alzheimer's disease-modifying treatments

Neurobiology of Aging

Volumn 32, Issue SUPPL. 1, 2011, Pages

  Reiman, Eric M ^a  

^a TRANSLATIONAL GENOMICS RESEARCH INSTITUTE   (United States)

Author keywords

Alzheimer's disease; Biomarkers; Brain imaging; Cerebrospinal fluid; Clinical trials; Dementia; Magnetic resonance imaging; Mild cognitive impairment; Positron emission tomography; Preclinical; Presymptomatic; Prevention; Treatment

Indexed keywords

APOLIPOPROTEIN E4; APOLIPOPROTEIN E4 EPSILON; FLUORODEOXYGLUCOSE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; APOLIPOPROTEIN E4 EPSILON GENE; ARTICLE; BRAIN ATROPHY; BRAIN METABOLISM; BRAIN REGION; CEREBRAL METABOLIC RATE FOR GLUCOSE; COGNITION; EARLY DIAGNOSIS; GENE; GLUCOSE METABOLISM; HETEROZYGOTE; HIPPOCAMPUS; HOMOZYGOTE; HUMAN; MILD COGNITIVE IMPAIRMENT; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL;

ALZHEIMER DISEASE; BIOLOGICAL MARKERS; BRAIN; CLINICAL TRIALS AS TOPIC; ENDPOINT DETERMINATION; FLUORINE RADIOISOTOPES; FLUORODEOXYGLUCOSE F18; GLUCOSE; HUMANS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS;

EID: 80955148926     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2011.09.007     Document Type: Article

References (9)

1. Alexander G.E., Chen K., Pietrini P., Rapoport S.I., Reiman E.M. Longitudinal PET evaluation of cerebral metabolic decline in dementia: a potential outcome measure in Alzheimer's disease treatment studies. Am. J. Psychiatry 2002, 159:738-745.
2. Chen K., Ayutyanont N., Langbaum J.B., Fleisher A.S., Reschke C., Lee W., Liu X., Bandy D., Alexander G.E., Thompson P.M., Shaw L., Trojanowski J.Q., Jack C.R., Landau S.M., Foster N.L., Harvey D.J., Weiner M.W., Koeppe R.A., Jagust W.J., Reiman E.M. Characterizing Alzheimer's disease using a hypometabolic convergence index. Neuroimage 2011, 56:52-60. Alzheimer's Disease Neuroimaging Initiative.
3. Chen K., Langbaum J.B., Fleisher A.S., Ayutyanont N., Reschke C., Lee W., Liu X., Bandy D., Alexander G.E., Thompson P.M., Foster N.L., Harvey D.J., de Leon M.J., Koeppe R.A., Jagust W.J., Weiner M.W., Reiman E.M. Twelve-month metabolic declines in probable Alzheimer's disease and amnestic mild cognitive impairment assessed using an empirically pre-defined statistical region-of-interest: findings from the Alzheimer's Disease Neuroimaging Initiative. Neuroimage 2010, 51:654-664. Alzheimer's Disease Neuroimaging Initiative.
4. Jagust W., Reed B., Mungas D., Ellis W., Decarli C. What does fluorodeoxyglucose PET imaging add to a clinical diagnosis of dementia? Neurology 2007, 69:871-877.
5. Landau S.M., Harvey D., Madison C.M., Reiman E.M., Foster N.L., Aisen P.S., Petersen R.C., Shaw L.M., Trojanowski J.Q., Jack C.R., Weiner M.W., Jagust W.J. Comparing predictors of conversion and decline in mild cognitive impairment. Neurology 2010, 75:230-238. Alzheimer's Disease Neuroimaging Initiative (ADNI).
6. Reiman E.M., Caselli R.J., Chen K., Alexander G.E., Bandy D., Frost J. Declining brain activity in cognitively normal apolipoprotein E epsilon 4 heterozygotes: a foundation for using positron emission tomography to efficiently test treatments to prevent Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:3334-3339.
7. Reiman E.M., Langbaum J.B.S. Brain imaging in the evaluation of putative Alzheimer's disease slowing, risk-reducing and prevention therapies. Imaging and the Aging Brain 2009, 319-350. Oxford University Press, New York. W. Jagust, M. D'Esposito (Eds.).
8. Reiman E.M., Langbaum J.B.S., Tariot P.N. Alzheimer's Prevention Initiative: a proposal to evaluate presymptomatic treatments as quickly as possible. Biomark Med 2010, 4:3-14.
9. Silverman D.H., Small G.W., Chang C.Y., Lu C.S., Kung De Aburto M.A., Chen W., Czernin J., Rapoport S.I., Pietrini P., Alexander G.E., Schapiro M.B., Jagust W.J., Hoffman J.M., Welsh-Bohmer K.A., Alavi A., Clark C.M., Salmon E., de Leon M.J., Mielke R., Cummings J.L., Kowell A.P., Gambhir S.S., Hoh C.K., Phelps M.E. Positron emission tomography in evaluation of dementia: regional brain metabolism and long-term outcome. JAMA 2001, 286:2120-2127.